Russian Medical Development: News

WHO confirms the quality of the Russian influenza vaccine "Flu-M", 02.27.2023.

The FMBA reported that WHO confirmed the quality of the Russian influenza vaccine "Flu-M".

MOSCOW, February 27 - RIA Novosti. The World Health Organization has confirmed the quality of the Russian influenza vaccine Flu-M, developed by specialists from the Federal Medical and Biological Agency, the press service of the Federal Medical and Biological Agency of Russia reported.

"As part of the prequalification procedure, two independent laboratories of the World Health Organization ( WHO ) confirmed the high quality of the Flu-M flu vaccine developed by the St. in the message.

The evaluation was carried out according to the WHO requirements for influenza vaccine. The test results confirmed the acceptability of the seasonal flu vaccine, the press service said.

"Own technology for the production of vaccines from a strain to a finished product makes it possible to achieve high-quality purification of antigens, in which the content of ovalbumin (the main allergen of a chicken egg) is in the range of 1-2 ng at a dose, which is a thousand times less than the permissible norms," said the head of the FMBA of Russia Veronika Skvortsova , whose words are given in the message.

https://ria.ru/20230227/vaktsina-1854720098.html

Doctors in Donetsk extracted a bullet from a working heart


In Donetsk, doctors were able to remove a bullet from the pericardium of a working heart. This was announced on Saturday, March 5, by the Minister of Health of the DPR Dmitry Gartsev.

The 36-year-old patient was operated on by doctors of the Donetsk Clinical Territorial Medical Association (DOKTMO).

The day before, the patient was admitted to the hospital with a blind shrapnel wound. The study revealed that there was a bullet in his pericardium (heart sac). Heart surgeons extracted it in a working heart condition.

"The operation was successful. The patient was transferred to the department, where he receives neurological therapy, antibiotic prophylaxis, physiotherapy and daily dressings. The patient is recovering, "one of the doctors told RIA Novosti.

Earlier, on March 3, Donetsk doctors in military equipment removed the mine fuse from the patient's body. The operation was successful for both the patient and the surgeon.

Before that, Donetsk medics saved a man after a shrapnel hit his heart.

https://translated.turbopages.org/proxy_u/ru-en.en.15b7586e-640486de-e9b03937-74722d776562/https/iz.ru/1479064/2023-03-05/vrachi-v-donetcke-izvlekli-puliu-iz-rabotaiushchego-serdtca?main_click

An enterprise for the production of insulin was built in Serpukhov, 04.06.2023.

A production and warehouse complex for the assembly of syringe pens with cartridges for insulin preparations (Rinsulin R, Rinsulin NPH) was built in the urban district of Serpukhov, near the existing warehouse for finished insulin products - in the village of Obolensk.

The area of ​​the enterprise for the production of insulin was 2.2 thousand square meters. The plant will produce 21 million syringe pens per year. Therefore, the production of the substance will double. 17 people can find a job there.

In Serpukhov, the domestic biotechnology company Geropharm launched a full-cycle plant for the production of genetically engineered human insulin back in 2013. To expand production, the enterprise attracted a loan from the Russian Agricultural Bank in the amount of 1.8 billion rubles. The investment transaction made it possible to modernize the production of the insulin substance in Pushkin in St. Petersburg and create a new packaging and bottling site for medicines in the village of Obolensk, Serpukhov city district.

The construction of a complex for the production of import-substituting insulin began in June 2021. A few days ago, a final inspection took place at the facility. The Glavgosstroynadzor of the Moscow Region issued a conclusion to the developer LLC "Geropharm" on compliance with the requirements of the project documentation.

https://sdelanounas.ru/blogs/150822/

More than 60 patients of the rehabilitation and educational center of the Central Military Clinical Hospital on April 28 became owners of state awards and documents for obtaining housing. In a medical facility created last year specifically for members of the SVO, the military successfully completed a recovery course. This center is just one of the elements of the Russian military medicine system, which has shown its high level. We are talking about the effectiveness of inpatient treatment, evacuation systems from the battlefield,and emergency care. It is possible that such military-medical complexes will become products of the Russian defense industry in demand on world markets. What is the current state of Russian military field medicine and the export prospects of specialized equipment-in the material "Izvestia".

Invaluable experience

On April 28, Yuri Bobrov, Acting Head of the Russian Defense Ministry's Personnel Department, visited the Rehabilitation and Educational Center of the Central Military Clinical Hospital. More than 20 servicemen received state awards from his hands, and more than 40 became owners of documents for obtaining housing. In the center, participants not only undergo rehabilitation, but also have the opportunity to get additional education and a new profession. The creation of such institutions is only one of the elements of improving the system of Russian military medicine.

Medical support for military personnel is of the same, if not greater, importance in comparison with the actual military means. In every conflict over the centuries, warlords have tried to save the lives of as many fighters as possible by providing them with timely assistance so that they recover and return to service as soon as possible. This approach is still relevant today.

For example, during the nine years of the 40th Soviet Army's presence in Afghanistan, military doctors managed to reduce the mortality rate in army medical institutions by half. And the number of errors in the provision of medical care during this period decreased by more than 20 times. For the speedy delivery of the wounded, aviation was actively used — in those units that fought in the mountains, 85-90% of the wounded and sick were evacuated by helicopters.

Overall, 77.9% of the wounded returned to service during the Afghan war. By the end of the campaign, this number had increased from 74.1% to 82.4%. In the course of military operations in Chechnya, this figure was 78.3%, in Dagestan — 84.3%.

During a special military operation in Ukraine, according to the Russian Defense Ministry, up to 97% of the wounded return to service. At the same time, at different stages of SVR, the proportion of patients in severe and extremely severe conditions reached 24-27%, in the state of moderate severity-about half, light injuries are recorded in 20-22%. According to the nature of injuries, 70% are mine-explosive wounds, 10% each-diseases, injuries and gunshot wounds.

It is obvious that one of the most effective ways to save the lives of the wounded is to provide them with professional medical care in hospitals as soon as possible. This requires a professional, well-equipped medical service.

The medical service of the Russian army probably reached the peak of its capabilities at the beginning of SVO, having been seriously reformed first in 2008-2010, and then in 2012-2014. At the last stage, work was accelerated on the formation of 50 medical companies capable of providing military personnel with all types of medical care — from the first to special. Each of them had to have an infirmary for 50-75 beds and an outpatient clinic for 150-200 visits per day.

Unique equipment

At the same time, units of the military level of the medical service of the Russian Armed Forces were equipped with modern equipment and deployment facilities based on PSM-6 pneumatic frame structures. They were purchased for all 50 medical companies. 35 medical companies were completely equipped and re-equipped with equipment, which were located in standard buildings and in standard equipment.

The coronavirus epidemic turned out to be a real-world test — during this period, the Ministry of Defense deployed nine mobile prefabricated hospitals in various regions of the country. The experience of sending Russian military doctors to Italy, where they also helped fight the infection, was positive.

Military medics also received new samples of special sanitary equipment. By the 2010s, the bulk of the old Soviet specialized cars were outdated morally and physically. This forced the development and purchase of new samples. If the BMM-80 Symphony combat medical vehicle on the GAZ-59039 chassis did not become mass-produced, then the protected tactical vehicle (ZSA) proved its effectiveness. It is available in two versions — the ZSA-T medical transporter (for searching, collecting and removing wounded from the battlefield) and the ZSA-P battalion medical station vehicle (for transporting property and deploying a battalion medical center on its base). These machines are actively used in the course of SVO and, according to available data, have shown themselves to be the most advantageous in terms of security.

Thus, Russian field medicine maintains its leading position in the world, improving the material base and skills of personnel. Such a comprehensive offer may also be in demand on the global market. A potential customer can receive turnkey training and / or retraining of military doctors based on the experience of recent conflicts, construction and equipping of special equipment for stationary and mobile hospitals, delivery of sanitary ground and aviation equipment.

And in the latter case, it can be both UAV transporters of medicines, canned blood, etc., and ambulance planes and helicopters of the IL-76MD "Scalpel-MT" type, ambulance Mi-8 and Ansat. This may be a unique Russian offer on the global market.

https://translated.turbopages.org/proxy_u/ru-en.en.385918c9-644e4fdd-77af2462-74722d776562/https/iz.ru/1505531/andrei-frolov/zdorovaia-tendentciia-kak-voenno-polevaia-meditcina-spasaet-zhizni-97-ranenykh

97% of the wounded that survive, maybe.

https://www.rt.com/business/577569-russia-rosatom-medical-devices/

Rosatom has launched a new manufacturing branch to replace Western medical devices used inside Russia

In the "Military Medical Academy named after S.M.Kirov", the graduation of servicemen who have completed a course of additional vocational education, who have limitations due to injuries received during the performance of tasks within the framework of a special military operation took place.

The head of the Department of Military Education – Deputy Head of the Main Personnel Department of the Ministry of Defense of the Russian Federation, Major General Igor Muravlyannikov conveyed the words of gratitude from the Minister of Defense of the Russian Federation, Army General Sergei Shoigu for the courage, bravery and bravery shown in the performance of military duty. The servicemen were awarded housing documents, certificates of completion of the course of additional vocational education, military ranks, certificates of a combat veteran and state awards.

The event was also attended by the head of the branch "Western" FSAU "Roszhilkompleks" of the Ministry of Defense of the Russian Federation Yuri Maulin.

About fifty-five servicemen were handed housing documents. Specialists of housing authorities have already selected and prepared places of residence in the selected regions of the country for officers and contractors who decided to continue military service after treatment, rehabilitation and professional retraining.

Ruslan Makiev, Deputy head of the Academy for Academic Affairs, Colonel of the Medical service, told about the program of further rehabilitation of servicemen and medical support at new places of military service, "In order to restore the lost functions, modern prostheses have been selected, manufactured and customized for each of you. A course of training in the use of them was conducted. An individual rehabilitation program has been developed for each of you, according to which, in the future, measures will be taken to maintain the prostheses and replace them if necessary."

Also, the distinguished servicemen were awarded fifteen state awards, including eight Orders of Courage, six medals for Bravery and the Zhukov medal, earlier a Decree of the President of Russia was issued on awarding these servicemen.

The Minister of Defense of the Russian Federation decided to ensure the possibility of further military service for all servicemen who were injured during a special military operation (optional). The new specialties received will allow the wounded servicemen to continue serving in new military positions in the organizations of the Ministry of Defense.

For reference:

For each serviceman, a military position is introduced in military commissariats, military units, institutions and organizations of the Ministry of Defense of Russia. In order to complete military service in these positions, military personnel must be trained to perform their duties.

The training programs include:

the basic part, which provides for the study of federal legislation and regulatory legal documents in the field of state defense and mobilization work, as well as the activities of military commissariats;
the variable part, the content of which is aimed at training in the performance of duties in the position to which the serviceman is appointed.

The final certification of military personnel is planned in the form of an interview. Upon completion of training, the relevant documents will be issued to the persons who have successfully mastered the training program.

All teaching materials, electronic textbooks and other electronic educational resources for conducting training sessions have been developed and are ready for training.

For the implementation of educational programs, qualified teaching staff of the Military Medical Academy named after S.M.Kirov was selected from among candidates of sciences with experience in the appropriate training of officers.

This is only one of the directions of a large-scale program of measures aimed at the social rehabilitation of wounded servicemen, approved by the Minister of Defense of the Russian Federation.

The program also provides for measures to restore health and medical rehabilitation, an individual approach to determining further service assignments and a special procedure for military service, the provision of social benefits and guarantees, as well as housing.

https://function.mil.ru/news_page/country/more.htm?id=12470488@egNews

Golikova announced the production in Russia of 62% of drugs consumed, 06.19.2023.

Golikova: more than 62% of pharmaceuticals consumed in the country are produced in Russia.

Medicines are produced in Russia "in almost all segments of the pharmaceutical market," Deputy Prime Minister Tatyana Golikova said at an operational meeting with Prime Minister Mikhail Mishustin, the government's press service reports.


According to her, “due to the development of domestic production, 62% of all drugs consumed in the country are produced in the territory of the Russian Federation.” Golikova noted that, according to Rosstat, at the end of 2022, the volume of drug production amounted to 608 billion, which is an increase of 11% compared to 2021.

At the same time, Golikova noted that as part of the list of essential and essential medicines for medical use, a technological opportunity was created to produce according to 667 international generic names out of 815.

On June 19, the government approved a strategy for the development of the pharmaceutical industry until 2030. The main tasks, in particular, include supporting the organization of the production of medicines and their export, the elimination of administrative barriers, the accelerated introduction of new technologies and the training of scientific and industrial personnel for the industry.

In the next eight years, the share of Russian production of full-cycle drugs on the market “under the current conditions of current challenges” should be increased to almost 70%, Mishustin said.

After the start of the military operation in Ukraine, Western countries imposed sanctions against Russia. After that, the German company Bayer, the American MSD and Pfizer, as well as the Swiss Novartis reported about the restriction of activities in the country. They have suspended their investments in the country. Eli Lilly from the USA, which produces Cialis for the treatment of erectile dysfunction and the neuroleptic Zyprexa, has stopped supplying non-essential drugs to Russia.

https://www.rbc.ru/rbcfreenews/6490b35c9a79471957b648fa

It will take 8 years to get up by 8%?

Either these are the laziest most retarded pharmacy companies or cheap motherfuckers. I bet India can do 8% within 1 year. Not even.

The EXAR-34 exoskeleton for rehabilitation of patients with arm injuries and disorders was first developed in 2013 by a team of scientists from Russia's Volgograd Medical University led by Professor Alexander Vorobyov.
Veteran Andrei Semikashev, who had his right arm seriously injured during the special military operation in Ukraine, has been fitted with an EXAR 34 exoskeleton designed especially for him.
Within a few weeks after starting to use the exoskeleton, the officer was able not only to lift his arm, but also to pick up a mug and even use a screwdriver.
Semikashev went to the front as a volunteer. During fighting he was seriously wounded and his right arm was severely damaged. But thanks to the help of the developers of the EXAR-34 exoskeleton, he can now move his arm freely and he has been able to return to his profession of a construction worker and has enrolled in an art studio.
"The exoskeleton relieves the arm, let's say it cancels out gravity. That's why even a weak muscle impulse helps me lift my arm and perform movements that were impossible after the injury. With its help, I was able to do various everyday things, even use a screwdriver," says Andrei, explaining how the EXAR-34 works.

https://sputnikglobe.com/20230701/russian-scientists-design-exoskeleton-for-special-military-op-veteran-1111602424.html

Scientists of the Kurchatov Institute have created a biodegradable cage that firmly connects the vertebrae, and after their fusion, in a given time, it is replaced by the patient's bone tissue.

Spinal cage is a construction that is installed in place of a destroyed intervertebral disc during spinal surgery to fuse adjacent vertebrae damaged as a result of injuries or diseases.

Currently, non-degradable materials are used to create such structures, which remain inside the body forever, and can potentially cause complications.

The task of creating a spinal cage of a new generation is jointly solved by scientists of the Kurchatov Institute and the Academician B.V. Petrovsky RNC. One of the main requirements for scientists is that the cage be created from biodegradable material. According to the sketches of doctors in the laboratory of polymer materials of the Kurchatov complex of NBICS-nature-like technologies, a cage design was developed, its model was created based on a CT scan of the patient, and then an implant was made on a 3D printer.

The cage consists of two parts made of polymers: a frame that takes on the entire load, and a zone with a porous structure.

"Bone tissue has a large porosity, from 50 to 90%, and there are a number of reasons for this – the diffusion of nutrients, the excretion of various products from the body. Therefore, one of the requirements for the implant is porosity," says Nikita Sedush, head of the laboratory of polymer materials at the Kurchatov Complex of NBICS–nature–like technologies. – We were faced with a big question – how to recreate such a porous structure? We decided to use a system of elementary cells built on the basis of a gyroid surface (a gyroid is a complex structure, infinitely connected and repeating in all three dimensions, devoid of straight lines and planar symmetry). Its parameters can be calculated by mathematical methods and varied, thereby precisely adjusting the porosity of the resulting structure and its mechanical properties. This allows you to adjust to the bone tissue where the implant will be installed. For example, the cages for the cervical spine and for the lumbar spine will have different cell structures."

Such a complex "geometry" is not easy to translate into reality: classical methods of material processing are no longer suitable here. But with the help of additive technologies (3D printing), you can create products of the desired structure and adjust their properties. These technologies open up opportunities for creating both standard and personalized products: it is possible to make a cage that perfectly repeats the surface of the vertebrae of a particular patient, and this will optimally compensate for the change in anatomy as a result of injury.

The next important task was to obtain a biodegradable material for the cage frame with the necessary properties. "In our laboratory, we work a lot with polylactide and its copolymers of various compositions. These are materials that we have studied well – we know how to synthesize them and adjust their properties," says N. Sedush. "The results of our research have shown that polylactides can replace non–degradable materials for the manufacture of medical structures."

The polylactide cage will completely decompose in the postoperative period. Preliminary tests have shown that it can withstand a compression load of more than 500 kg. The first samples have been made, which will be tested on animals in the near future. "The advantage of these products is that they are both biodegradable and personalized. There are no analogues in Russian medicine yet," N. Sedush comments.

In addition, scientists are working on a bioactive coating that can be applied to the surface of the cage to speed up the fusion of the vertebrae.

http://nrcki.ru/product/press-nrcki/-47583.shtml

Sobyanin and Manturov opened a new drug production plant in Zelenograd, by Lyubov Protsenko for Rossiyskaya Gazeta. 08.21.2023.

The new pharmaceutical plant, which was launched in Zelenograd by Deputy Prime Minister of the Russian Federation, Minister of Industry and Trade Denis Manturov and Moscow Mayor Sergei Sobyanin, will produce 26 vital drugs, many of which have not been produced in our country before. Anticancer and drugs for the treatment of cardiovascular, autoimmune diseases, for the treatment of HIV infection and many others. An enterprise was built on the site "Alabushevo" of the special economic zone "Technopolis" Moscow".

“Together with the Ministry of Industry, five years ago we set the task of localizing the production of imported drugs in Russia as much as possible, avoiding their import from abroad. This is especially true of vital drugs in the field of oncology,” said Sergei Sobyanin. “During this time, 8 plants, in the coming years we will build seven more.The results are as follows: this year the volume of their production in Moscow increased by 67.5%, more than two-thirds." So step by step, according to the head of the city, our country is becoming more and more independent in providing Russians with medicines.

Noting how important it is when a subject of the Federation takes on such a task, Denis Manturov thanked the Moscow government for supporting the development of industry: “This is such a joint collaboration of the state represented by the federal government, of course, with your support and with the benefits that are provided to the investor, and directly the investments themselves are already from the company. I believe that this is the most effective way to reduce the risks and costs of entrepreneurs."

Moscow, which is interested in creating a new plant, signed an offset contract with the R-Pharm group of companies in 2018. In accordance with it, the company undertook to build a production complex with an area of ​​more than 30.5 thousand square meters in Alabushev. To organize the production of 26 international non-proprietary names of medicines in the built workshops, and the government of the capital guaranteed their purchase for seven years. The Industry Development Fund issued a loan of 2 billion rubles. The total investment amounted to 6.99 billion rubles. And this summer, construction was completed.

We are walking along one of the ultra-modern lines of the new plant. Chief engineer Oleg Dyashkin says: "Highly active preparations are produced here. The whole process is concentrated - from washing of vials, sterilization, bottling, capping, final washing, visual quality control and lyophilization." The visible part of the production is located on the first floor of the building, and there is also a second floor, from where the line is supplied with water, air and other components. There are also biofilters that protect the environment from emissions of harmful substances. The line is served by only four operators, despite the fact that its capacity is 200 ready-made bottles of medicine per minute.

Nearby is another site - for the packaging of drugs in capsules. "It produces drugs in a non-contact way - 9,000 blisters per hour," chief mechanic Anton Pankratovsky demonstrates the operation of the new equipment.

Denis Manturov recalled that in 2022 the plant refused foreign suppliers of components for managing engineering systems. And today, controllers and components from a Russian manufacturer are successfully used here to automate engineering systems. The situation is the same with the system for monitoring climatic parameters; at R-Opra it is made on a hardware and software system from a domestic company.

"The capacity of the enterprise will allow to produce 270 million packages of drugs per year. I am sure that soon doctors and patients will appreciate the quality and availability of domestic drugs - antitumor drugs produced at this plant will go into circulation in 2024," Denis Manturov concluded.


Vasily Ignatiev, General Director of R-Pharm, noted that the launch of the first offset plant in the capital is a significant event for the company: “We took advantage of a wide range of support measures from both the Moscow Government and the Ministry of of the Industrial Development Fund. And of course, the offset itself is still the main thing, it is the backbone, the backbone of the entire project."

The new enterprise has the status of a resident of the Technopolis Moscow special economic zone, which gives it access to significant benefits. Among them - a zero rate on taxes on property, land and transport tax, a 10-fold reduction in income tax, the possibility of buying land at a reduced price. The company also receives financial support from the Moscow Industry and Entrepreneurship Support Fund in the form of compensation for part of the interest rate on a preferential investment loan.

Let me remind you that in recent years Moscow has become one of the largest manufacturers of medicines and medical devices in Russia. There are 95 enterprises operating in the city, which employ over 15 thousand people. The most important part of this branch of the capital has become a cluster of enterprises operating at the sites of Technopolis Moscow in Zelenograd and Pechatniki. Its investment program of 41.4 billion rubles provides for the development of the production of 128 generic drugs, of which 98 have never been produced in Russia. This will provide more than 80% of the need for domestic oncological drugs.

https://rg.ru/2023/08/21/reg-cfo/sobianin-i-manturov-otkryli-novyj-zavod-po-proizvodstvu-lekarstv-v-zelenograde.html

11 (!) new hospitals/clinics opened in Moscow on August 28th, reports mayor Sobyanin.
https://m.vk.com/video265870743_456240523

Some were old and now re-opened after major renovations, so 11 "new" isn't strictly true, but still.

"Promomed" will replenish the drug market with Russian drugs against diabetes, 09.19.2023.

Promomed will replenish the market with Russian drugs for the treatment of diabetes mellitus.

MOSCOW, September 19 – RIA Novosti. The pharmaceutical company Promomed is introducing import-substituting drugs for the treatment of diabetes to the Russian market, the manufacturer told RIA Novosti.

"The Promomed group of companies <...> announces the launch on the market of the first domestic drug of the group of "glutides" (agonists of glucagon-like peptide receptors) for the treatment of patients with type 2 diabetes mellitus, overweight and obesity, as well as for the prevention of the development of heart disease. -vascular complications associated with these diseases,” the statement says.

It is clarified that the new line includes the drugs "Enligria", "Quinliro" (international nonproprietary name - liraglutide) and "Quincenta" (international nonproprietary name - semaglutide).
Liraglutide is one of the most powerful stimulants of insulin production, allowing you to achieve stable control of blood sugar levels. The drug also slows digestion, helping to avoid sudden spikes in sugar after meals. Used as an independent medicine or in combination with others.

Thus, a drug under the trade name "Enligria" is liraglutide, which is available in the form of a pre-filled pen syringe. This drug received a registration certificate on September 18 and will be available in pharmacies in the second ten days of October. "Quinliro" and "Quincenta" are at the stage of state registration.

As the pharmaceutical company emphasized, these drugs will make it possible to close the shortage of similar drugs that arose last year due to the cessation of supplies from the only manufacturer.

It is noted that Promomed produces these drugs in partnership with another pharmaceutical company, the Medsintez plant.

Promomed Group of Companies is a Russian pharmaceutical company that produces five main groups of drugs: antitumor, antiviral, endocrinological, neurological and antibiotics. We are talking about more than 300 types of medicines, 80 percent of which are on the list of vital and essential medicines (VED).

https://ria.ru/20230919/rynok-1897243990.html

Clinical trials of the diabetes drug Semavik have been completed in Russia, 09.19.2023.

Clinical trials of the diabetes drug Semavik have been completed in Russia.

MOSCOW, September 19 – RIA Novosti. The Russian pharmaceutical company Geropharm has completed clinical trials of the diabetes drug Semavik, a domestic analogue of the Danish Ozempic, the organization told RIA Novosti.

“Several companies are preparing to introduce analogues of Ozempic to the Russian market. Geropharm has successfully completed clinical studies, during which the comparability of the analogue and the reference drug in terms of biological comparability was proven <...> It is expected that the drug Semavik , which is already being registered, will become the first analogue of Ozempic <...> All necessary documents have already been submitted to the regulators,” the statement says.

At the end of March, Roszdravnadzor reported that in November last year it received a notification from Novo Nordisk, the manufacturer of Ozempic (the active ingredient semaglutide), about the planned cessation of supplies to Russia. At the same time, the drug will be available to patients at least until December of this year. At the end of June, Geropharm received permission for clinical trials of an analogue of Ozempic.

It is clarified that Novo Nordisk has a valid patent for the molecule until 2035, so analogues of the drug can be registered through the compulsory licensing procedure.

As noted by Geropharm, the new drug will be included in the list of vital and essential drugs (VED), and its cost will be fixed by the state and will be about six thousand rubles. Now the price for one package of injectable semaglutide when purchased on the gray market ranges from 15 to 30 thousand rubles.

According to the general director of the company, Peter Rodionov, the availability of a drug based on semaglutide in Russia is a guarantee of patient safety. He emphasized that this is a vital medicine that is used in a course, so it is important to ensure its availability in the usual form of release.

The production capabilities of Geropharm allow us to begin production of the drug at our own plant now and fully satisfy the needs of the domestic market, Rodionov added.

https://ria.ru/20230919/diabet-1897345937.html

The unique equipment was created at the MISIS University. A bioprinter in the form of a robotic arm will be able to print live cells directly on the patient in the operating room.

To do this, scientists have developed special software. First, the software and hardware complex of the bioprinter scans the defect and creates a three-dimensional model of it, and then fills the area with a hydrogel with living cells.

The movements of the robot arm and the submission of the material occur along the trajectory generated by the program. It takes into account not only the curves of the body, but even the patient's breathing. To do this, an integrated feedback system with a laser sensor is integrated into the device designed for the robot's interaction with the environment.

Expert: The effectiveness of the Russian cancer drug can reach 100%, 09.29.2023.

Pogrebnyakov: the effectiveness of the new Russian cancer drug reaches 100%.

MOSCOW, September 29 – RIA Novosti. The effectiveness of a new domestic drug for the treatment of cancer with the help of light in some cases can reach 90-100 percent, the head of the department - a doctor for x-ray endovascular diagnostics and treatment of the department of x-ray surgical methods of diagnosis and treatment of the department of interventional radiology of the Research Institute of Clinical and Experimental Radiology of the Federal State Budgetary Institution "National Medical Research Center of Oncology" told RIA Novosti named after N. N. Blokhin" of the Russian Ministry of Health, Candidate of Medical Sciences Igor Pogrebnyakov.

“The drug can be used in the treatment of patients with various types of tumors of the gastrointestinal tract, bile ducts, genitourinary system, upper respiratory tract and skin. At certain stages of the disease, if all indications for use are followed, the effectiveness can reach 90-100 percent,” he said.

According to the specialist, the product has several domestic analogues, the experience of using which was taken into account during production. This type of drug is well tolerated by patients and has no serious side effects, the doctor said.

The only absolute contraindication to its use is porphyrin disease, which is rare in Russia, Pogrebnyakov clarified.
The day before, Moscow Mayor Sergei Sobyanin announced that a drug for the treatment of cancer with the help of light began to be produced in the capital, the company plans to produce up to 40 thousand bottles per year.

As the head of the city noted, in the early stages of the disease, this method of treatment can replace surgical intervention. The drug is administered to the patient, it accumulates in the tumor cells, then is activated by laser or LED radiation. After this, the neoplasm is almost completely destroyed.

https://ria.ru/20230929/preparat-1899547258.html

Would be nice to know what the basis of this drug is. Cancer cells have defective mitochondria (thus the anaerobic glucose metabolism) and metastatic cancer cells
are corrupted macrophages that have ingested the broken mitochondria of the initial population of cancer cells in tumors. That is why these converted cancer cells
can leave the tumor by entering the vascular system and exiting it. Any tissue cell that becomes cancerous cannot do this and you just have formation of tumors.
If a drug can disrupt the cancer-ification of macrophages it would essentially be a cure.

Drugs that can get oxygen into cancer cells would be effective since this is lethal for them. But the reference to light in the article suggest that this is some sort
of selective delivery of pigments to cancer cells that can then be killed by exposure to the right light frequency. If this is something in the red to infra-red range
then tumors quite deep in the body can be treated.

A “smart” blood pressure monitor has been developed in Russia, 09.30.2023.

NTI: Russia has developed a tonometer watch that sends a person’s indicators to the doctor.

MOSCOW, September 30 – RIA Novosti. In Russia, they have developed a “smart” tonometer watch that measures a person’s pulse, blood pressure and ECG and, if necessary, sends information to the doctor, the press service of the National Technological Initiative (NTI) told RIA Novosti.

“A team of developers from Kazan came up with a tonometer in the format of a smart watch with data analysis by artificial intelligence. Such a device is planned to be introduced into a unified ecosystem of remote health monitoring according to the “Clinic at Home” model. The project went through an acceleration program at the design and educational intensive “Archipelago 2023” , - NTI reported.

In general, as the developers noted, the gadget is configured personally for a person’s tasks through a mobile application associated with the device and takes measurements throughout the day - ECG, pulse, blood pressure, as well as reading the user’s activity. Next, the received data is analyzed by AI and, if necessary, push notifications are sent, and monitoring information is sent to the doctor to adjust therapy.

“The uniqueness of the project lies in the fact that the device is part of a medical ecosystem that is built around the user. For example, there are Korean watches that also perform an ECG, but their data is not analyzed and does not become part of the user’s medical history,” said project leader Linar Garifullin.

He noted that the gadget will become ahead of imports, and all data generated during monitoring will be stored in Russia with access for doctors.

“We are planning to obtain a registration product from Roszdravnadzor for our device, so it will combine a medical device and the functions of a familiar smartwatch,” added Garifullin.

As he also emphasized, the main difference between a blood pressure monitor and a smart watch is that the data from the latter cannot be used for medical purposes, so it is impossible to integrate them into the medical ecosystem.

The project is currently at the prototype stage; the developers plan to release the first batch of devices in 2024.

https://ria.ru/20230930/tonometr-1899609844.html

Thanks to prompt assistance on the battlefield, timely evacuation and high-tech medical care, more than 98% of those wounded during a special military operation are discharged with recovery, Russian Defense Minister Sergei Shoigu said at a conference call with the leadership of the Russian Armed Forces.

The head of the Russian Ministry of Defense noted that the mortality rate in hospitals is 0.43% and continues to decline. The survival rate of the wounded has been improved manifold.

Medical care for personnel is organized at a good level, Shoigu said. The minister dwelled in detail on providing assistance to the wounded in the area of ​​the line of combat contact. Wounded military personnel receive first aid on the battlefield most often in the first minutes after injury. Field hospitals have been deployed in close proximity to the front line, which are reinforced by experienced surgeons from central medical institutions.

Shoigu thanked military doctors and medical personnel for their conscientious service. According to him, front-line doctors show professionalism and courage, perform unique operations, saving the lives and health of our soldiers.

The Russian Defense Minister noted that the Russian army has the necessary number of military personnel to conduct a special operation. According to him, the General Staff has no plans for additional mobilization .

https://tvzvezda-ru.translate.goog/news/20231031236-RVGMQ.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-GB&_x_tr_pto=nui&_x_tr_hist=true

My take of the above is that out of 500 servicemen requiring treatment for wounds; 2 will die, 490+ will be released however that leaves 6-8 that will require long term care (probably for the rest of their lives) for spinal, head or mental, etc.
From several reports over the past months, it seems that Ukrainian wounded are less then or around 2 times per deaths while Russian wounded are at least 4 times battle deaths. Probably due to medical assistance received and the different way each side is fighting the SVO.

Prepare for future exports at a low cost to compete with the Danish stuff Ozempic worldwide.

An analogue of the Danish diabetes drug Ozempic has been registered in Russia., 10.06.2023.

"Geropharm": domestic diabetes drug "Semavik" registered in the Russian Federation.

MOSCOW, October 6 – RIA Novosti. The Geropharm company has registered a domestic analogue of Ozempic, a Danish drug for the treatment of diabetes, and production will be launched in the Moscow region, the pharmaceutical company told RIA Novosti.

“The drug Semavik from the Geropharm company has been registered in Russia, which will replace Ozempic, which left the country,” the press service said.

They noted that the manufacturer of the Danish drug, Novo Nordisk, completely stopped supplying it to Russia this year, despite the inclusion of segmalutide in the list of vital drugs (VED).

“The production of the drug “Geropharm” will be carried out at its own plant in the Moscow region, which allows the production of lyophilized forms, solutions and suspensions in vials, cartridges and syringe pens,” the company added.

In September, Geropharm told RIA Novosti that the cost of the Russian analogue would be about six thousand rubles.

Preparations containing segmalutide are used primarily for type II diabetes mellitus. As prescribed by a doctor, their use is also permissible for overweight or obesity.

https://ria.ru/20231006/semavik-1901018355.html